Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
NEO 
NeoGenomics Inc (NEO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: NEO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
14 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $11.25
1 Year Target Price $11.25
| 6 | Strong Buy |
| 2 | Buy |
| 6 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -28.59% | Avg. Invested days 39 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 971.65M USD | Price to earnings Ratio - | 1Y Target Price 11.25 |
Price to earnings Ratio - | 1Y Target Price 11.25 | ||
Volume (30-day avg) 14 | Beta 1.64 | 52 Weeks Range 6.08 - 19.11 | Updated Date 07/4/2025 |
52 Weeks Range 6.08 - 19.11 | Updated Date 07/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.61 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -11.54% | Operating Margin (TTM) -16.56% |
Management Effectiveness
Return on Assets (TTM) -2.75% | Return on Equity (TTM) -8.57% |
Valuation
Trailing PE - | Forward PE 222.22 | Enterprise Value 1218344497 | Price to Sales(TTM) 1.45 |
Enterprise Value 1218344497 | Price to Sales(TTM) 1.45 | ||
Enterprise Value to Revenue 1.81 | Enterprise Value to EBITDA -27.92 | Shares Outstanding 128695000 | Shares Floating 120342230 |
Shares Outstanding 128695000 | Shares Floating 120342230 | ||
Percent Insiders 1.19 | Percent Institutions 100.64 |
Upturn AI SWOT
NeoGenomics Inc
Company Overview
History and Background
NeoGenomics Inc. was founded in 2001. It has grown through acquisitions and organic growth to become a leading cancer testing and information services company.
Core Business Areas
- Pharma Services: Provides comprehensive testing and pathology services to pharmaceutical companies to support drug development and clinical trials.
- Clinical Services: Offers a range of cancer diagnostic, prognostic, and predictive testing services to community-based pathologists and oncologists. This includes tests like FISH, cytogenetics, flow cytometry, IHC and molecular tests (e.g. next generation sequencing).
Leadership and Structure
The leadership team includes Chris Smith (CEO), Dr. Maher Albitar (Chief Medical Officer), and other key executives. The company is structured around its clinical and pharma services divisions.
Top Products and Market Share
Key Offerings
- Next Generation Sequencing (NGS) Panels: Comprehensive NGS panels for various cancers. NeoGenomics does not publicly report exact market share numbers for NGS panels, but is a leading provider in this area, competing with companies like Foundation Medicine (part of Roche). Revenue from Clinical services account for bulk of company's revenue.
- Fluorescence In Situ Hybridization (FISH) Testing: FISH testing for various cancers. No specific market share data available for NeoGenomics, but is one of the services that drive revenue. Competition includes LabCorp.
- IHC Testing: NeoGenomics provides a variety of IHC tests. No specific market share data available for NeoGenomics.
Market Dynamics
Industry Overview
The cancer diagnostics market is growing due to increasing cancer incidence, advancements in technology, and demand for personalized medicine.
Positioning
NeoGenomics Inc is positioned as a key player in the cancer diagnostics market, particularly in specialized testing for oncologists, pathologists and biopharma. Key competitive advantages include its comprehensive test menu, expertise in oncology, and relationships with oncologists and pharma companies.
Total Addressable Market (TAM)
The global cancer diagnostics market size is expected to reach hundreds of billions of USD. NeoGenomics Inc is positioned to address a significant portion of this TAM, particularly within specialized oncology testing.
Upturn SWOT Analysis
Strengths
- Comprehensive test menu
- Strong relationships with oncologists
- Expertise in oncology
- Pharma services offerings
Weaknesses
- Past inconsistent profitability
- Reliance on reimbursement rates
- Debt levels.
Opportunities
- Expanding personalized medicine market
- Increasing demand for NGS
- Partnerships with pharmaceutical companies
- International expansion
Threats
- Increased competition
- Reimbursement rate pressures
- Technological advancements by competitors
- Economic downturns affecting testing volumes
Competitors and Market Share
Key Competitors
- LH
- DGX
- FMI
Competitive Landscape
NeoGenomics is a smaller player in the overall clinical lab market compared to LabCorp and Quest. Its focus on oncology testing provides a competitive advantage in that specific area.
Major Acquisitions
Clarient Diagnostics
- Year: 2012
- Acquisition Price (USD millions): 260
- Strategic Rationale: Expanded NeoGenomics' presence in hematopathology and solid tumor testing.
Growth Trajectory and Initiatives
Historical Growth: NeoGenomics Inc has experienced significant revenue growth over the past decade, primarily driven by acquisitions and expansion in cancer testing services.
Future Projections: Future growth projections depend on factors such as market expansion, technological advancements, and competition. Analyst estimates should be consulted for specific financial forecasts.
Recent Initiatives: Recent initiatives include expansion of pharma services, investment in new technologies, and strategic partnerships.
Summary
NeoGenomics Inc. is a cancer testing company with a comprehensive test menu and strong relationships with oncologists. While they have experienced significant growth, past inconsistent profitability and increasing competition remain challenges. The expansion of the personalized medicine market and strategic partnerships offer opportunities for future growth. They are still a smaller company than their competitors in the overall clinical lab market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is approximate and may vary based on source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NeoGenomics Inc
Exchange NASDAQ | Headquaters Fort Myers, FL, United States | ||
IPO Launch date 1999-11-02 | CEO & Director Mr. Anthony P. Zook | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 2200 | Website https://www.neogenomics.com |
Full time employees 2200 | Website https://www.neogenomics.com | ||
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through two segments: Clinical Services and Advanced Diagnostics. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.